Testing the most promising new therapies

On July 8, 2011, Editor-in-Chief Erika Rosenzweig convened a discussion among a group of physicians who work daily with pediatric PH patients to share their thoughts and experiences related to using new therapies with children. Contributing to the conversation were guest editor Dunbar Ivy, MD, Professor of Pediatrics, University of Colorado; Jeffrey A. Feinstein, MD, MPH, Associate Professor, Stanford University School of Medicine; Tilman Humpl, MD, PhD, Associate Professor, Pediatrics, University of Toronto; and Professor Maurice Beghetti, Head of Pediatric Subspecialties Division and Head of Pediatric Cardiology Unit, Children's University Hospital, Geneva, Switzerland.

Download Full-text

Stroke Care: Stroke Units, New Therapies, Advances and the Future

Understanding Stroke in a Global Context - Current Developments in Stroke ◽

10.2174/9781681085241116020007 ◽

2017 ◽

pp. 81-97

Author(s):

Jeyaraj D. Pandian ◽

Akanksha G. William ◽

Peter Langhorne ◽

Richard Lindley

Keyword(s):

Stroke Care ◽

Stroke Units ◽

New Therapies ◽

The Future

Download Full-text

UM Cure 2020: New therapies for uveal melanoma

Impact ◽

10.21820/23987073.2018.2.15 ◽

2018 ◽

Vol 2018 (2) ◽

pp. 15-17

Author(s):

Sergio Roman-Roman ◽

Marc-Henri Stern ◽

Samar Alsafadi ◽

Martine J. Jager ◽

Mehmet Dogrusöz ◽

...

Keyword(s):

Uveal Melanoma ◽

New Therapies

Download Full-text

Developing New Therapies for Delta Hepatitis: The Race Is On

Hepatology Communications ◽

10.1002/hep4.1685 ◽

2021 ◽

Vol 5 (4) ◽

pp. 556-558

Author(s):

Genco Gençdal ◽

Cihan Yurdaydin

Keyword(s):

New Therapies

Download Full-text

Integrative Biology of Diabetic Retinal Disease: Lessons from Diabetic Kidney Disease

Journal of Clinical Medicine ◽

10.3390/jcm10061254 ◽

2021 ◽

Vol 10 (6) ◽

pp. 1254

Author(s):

Warren W. Pan ◽

Thomas W. Gardner ◽

Jennifer L. Harder

Keyword(s):

Systems Biology ◽

Kidney Disease ◽

Diabetic Kidney Disease ◽

Vision Loss ◽

Retinal Disease ◽

Diabetic Kidney ◽

New Therapies ◽

Traditional Research ◽

Working Age ◽

Culture Models

Diabetic retinal disease (DRD) remains the most common cause of vision loss in adults of working age. Progress on the development of new therapies for DRD has been limited by the complexity of the human eye, which constrains the utility of traditional research techniques, including animal and tissue culture models—a problem shared by those in the field of kidney disease research. By contrast, significant progress in the study of diabetic kidney disease (DKD) has resulted from the successful employment of systems biology approaches. Systems biology is widely used to comprehensively understand complex human diseases through the unbiased integration of genetic, environmental, and phenotypic aspects of the disease with the functional and structural manifestations of the disease. The application of a systems biology approach to DRD may help to clarify the molecular basis of the disease and its progression. Acquiring this type of information might enable the development of personalized treatment approaches, with the goal of discovering new therapies targeted to an individual’s specific DRD pathophysiology and phenotype. Furthermore, recent efforts have revealed shared and distinct pathways and molecular targets of DRD and DKD, highlighting the complex pathophysiology of these diseases and raising the possibility of therapeutics beneficial to both organs. The objective of this review is to survey the current understanding of DRD pathophysiology and to demonstrate the investigative approaches currently applied to DKD that could promote a more thorough understanding of the structure, function, and progression of DRD.

Download Full-text